摘要
目的观察经鼻持续气道正压通气(NCPAP)联合大剂量盐酸氨溴索治疗新生儿肺透明膜病(HMD)的疗效。方法选择HMD患者42例,随机分成观察组22例和对照组20例,两组在相同综合治疗的基础上,观察组采用经鼻持续气道正压通气(NCPAP)联合大剂量盐酸氨溴索(商品名:沐舒坦)30mg(kg.d),分三次用5%葡萄糖20ml稀释后静脉滴注,对照组单纯采用NCPAP治疗,观察两组患儿治疗前、后临床表现、胸片、呼吸机参数变化、血气、血氧合指数变化、合并症、住院时间。结果治疗后观察组的临床症状体征、胸片、呼吸机参数、血气指标变化均较对照组明显改善,合并症少,住院时间缩短。结论NCPAP联合大剂量盐酸氨溴索治疗HMD疗效显著,经济安全,但应早期应用,可避免气管插管,减少机械通气率。
Objective To observe the efficacy of nasal continuous positive airway pressure （NCPAP） combining large dose of Ambroxol Hydrochloride to treat neonatal hyaline membrane disease. Methods Chose 42 HMD neonates in this study, allocated them randomly, 22 of them used in observation group, and 20 of them used in control group, on the base of the same combined therapy, observation group used nasal continuous positive airway pressure （NCPAP） combing large dose Ambroxol Hydrochloride（Mucosolvan, 30 mg/（ kg · d） ＋ 5% GS 20 ml, for three times）, and the control group only used NCPAP treatment. The clinical symptom before and after treatment, chest radiography, respiratory machine parameters, blood gases, blood oxygenation index, complications, length of stay of these two groups were observed. Results The clinical symptoms and signs, chest radiograph, respiratory machine parameters, arterial blood gas indicators in the observation group improved more significantly than in the observation group, and fewer complications, shorter hospital stay. Conclusion The efficacy of NCPAP combining large dose Ambroxol Hydrochloride to treat neonatal HMD is remarkable, economic and safe, but the therapeutic method should be used in earlier period, and the trachea cannula may be avoided and mechanical ventilation rate may be decreased.
出处
《现代医院》
2008年第5期29-31,共3页
Modern Hospitals
关键词
经鼻持续气道正压通气
盐酸氨溴索
肺透明膜病
新生儿
Nasal continuous positive airway pressure, Ambroxol hydrochlofide, Hyaline membrane disease, Neonates
